Liminatus Pharma, Inc. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Liminatus Pharma filed an 8-K on November 18, 2026 (reporting date November 16, 2026) disclosing Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The filing contains no substantive narrative text describing the actual event, counterparties, amounts, or business impact—only XBRL taxonomy and technical metadata. Without the underlying disclosure language, the nature and materiality of the event cannot be determined.
Why this rating
Filing is procedurally complete but substantively opaque; no event details disclosed; cannot assess materiality without event narrative.
Extracted items
- 8.01 other event
- 9.01 exhibits
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.